• Citer

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours

par Schöffski, Patrick;Adkins, Douglas;Blay, Jean Yves;Gil, Thierry ;Elias, Anthony A.D.;Rutkowski, Piotr;Pennock, Gregory G.K.;Youssoufian, Hagop;Gelderblom, Hans;Willey, R.;Grebennik, Dmitri D.O.
Référence European journal of cancer, 49, 15, page (3219-3228)
Publication Publié, 2013-10

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
Auteur:	Schöffski, Patrick; Adkins, Douglas; Blay, Jean Yves; Gil, Thierry; Elias, Anthony A.D.; Rutkowski, Piotr; Pennock, Gregory G.K.; Youssoufian, Hagop; Gelderblom, Hans; Willey, R.; Grebennik, Dmitri D.O.
Informations sur la publication:	European journal of cancer, 49, 15, page (3219-3228)
Statut de publication:	Publié, 2013-10
Sujet CREF:	Cancérologie
Mots-clés:	Adipocytic sarcoma
	Cixutumumab
	Ewing family of tumours
	Insulin-like growth factor receptor
	Leiomyosarcoma
	Rhabdomyosarcoma
	Soft-tissue sarcoma
	Synovial sarcoma
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2013.06.010
	info:pii/S0959804913004851
	info:scp/84884910107
	info:pmid/23835252